SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD. AND ITS SUBSIDIARIES

(Company Registration Number: 201134046D)

Unaudited Condensed Interim Consolidated Financial Statements
For the Three Months Ended 30 September 2026

Pursuant to Rule 705(2C) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") Listing Manual Section B: Rules of Catalist, Singapore Institute of Advanced Medicine Holdings Ltd. is required by SGX-ST to announce its quarterly financial statements.

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Company Registration No: 201134046D)

CONTENTS

		Page
A.	CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	3
B.	CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION	4
C.	CONDENSED INTERIM STATEMENTS OF EQUITY	6
D.	CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS	7
E.	NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS	9
F.	OTHER INFORMATION REQUIRED BY CATALIST RULES APPENDIX 7C	17

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Company Registration No: 201134046D)

A. CONDENSED INTERIM CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

		Group		
		Three Months Ended 30 September		
		2026	2025	Change
		(Unaudited)	(Unaudited)	
	Notes	S$	S$	%
Continued operations				
Revenue	5	**4,513,913**	4,121,862	10
Other income				
- Interest		**5,469**	5,362	2
- Others		**105,984**	102,807	3
Other gains/(losses)		**26,230**	(4,287)	n.m
Medical consultancy fees		**(462,741)**	(326,652)	42
Repair and maintenance		**(1,774,213)**	(1,671,511)	6
Purchase of inventories		**(333,847)**	(274,660)	22
Depreciation of property, plant and equipment		**(2,621,861)**	(2,885,006)	(9)
Amortisation of intangible assets		**(1,145)**	(2,286)	(50)
Short-term rental of premises		**(24,505)**	(28,305)	(13)
Employee compensation		**(2,739,377)**	(2,992,249)	(8)
Finance costs		**(991,998)**	(918,068)	8
Other operating expenses		**(1,527,981)**	(1,605,523)	(5)
Loss before tax		**(5,826,072)**	(6,478,516)	
Income tax expense	8	**-**	-	
Loss after tax and total comprehensive loss from continuing operations for the period		**(5,826,072)**	(6,478,516)	(10)
Discontinued operations				
Loss from discontinued operations, net of tax		**-**	(2,021)	n.m
Loss after tax and total comprehensive loss for the period		**(5,826,072)**	(6,480,537)	(10)

n.m - Not meaningful

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Company Registration No: 201134046D)

B. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION

		Group		Company	
		As at 30 September 2026	As at 30 June 2026	As at 30 September 2026	As at 30 June 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Notes	S$	S$	S$	S$
Equity					
Share capital	11	**209,329,342**	209,329,342	**209,329,342**	209,329,342
Other reserves		**(1,769,096)**	(1,769,096)	**(795,077)**	(795,077)
Accumulated losses		**(160,469,196)**	(154,643,124)	**(70,574,722)**	(69,964,077)
Total equity		**47,091,050**	52,917,122	**137,959,543**	138,570,188
Non-current assets					
Investment in subsidiaries	3(ii)	**-**	-	**153,175,530**	153,175,530
Other assets		**3,675,172**	3,621,401	**-**	-
Property, plant and equipment	3(i), 10	**107,836,865**	110,306,687	**-**	-
Intangible assets		**6**	1,151	**6**	1,151
Total non-current assets		**111,512,043**	113,929,239	**153,175,536**	153,176,681
Current assets					
Cash and bank balances		**7,235,916**	15,177,276	**5,945,975**	13,050,603
Inventories		**132,999**	109,097	**-**	-
Trade and other receivables	3(iii)	**2,966,008**	2,473,740	**7,651,502**	4,581,314
Other assets		**411,594**	411,594	**1,373**	4,800
Total current assets		**10,746,517**	18,171,707	**13,598,850**	17,636,717

B. CONDENSED INTERIM STATEMENTS OF FINANCIAL POSITION (CONTINUED)

		Group		Company	
		As at 30September 2026	As at 30 June 2026	As at 30September 2026	As at 30 June 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Notes	S$	S$	S$	S$
Current liabilities					
Trade and other payables		**10,761,265**	12,674,541	**459,124**	2,524,083
Loans from shareholders	12, 13	**23,956,773**	17,435,811	**23,956,773**	17,435,811
Borrowings	12	**935,319**	1,409,847	**935,319**	1,409,847
Lease liabilities		**3,233,650**	3,205,306	**-**	-
Provision for reinstatement costs		**278,612**	-	**-**	-
Total current liabilities		**39,165,619**	34,725,505	**25,351,216**	21,369,741
Net current liabilities		**(28,419,102)**	(16,553,798)	**(11,752,366)**	(3,733,024)
Non-current liabilities					
Loans from shareholders	12, 13	**3,463,627**	10,873,469	**3,463,627**	10,873,469
Lease liabilities		**27,533,663**	28,355,247	**-**	-
Provision for reinstatement costs		**5,004,601**	5,229,603	**-**	-
Total non-current liabilities		**36,001,891**	44,458,319	**3,463,627**	10,873,469
Net assets		**47,091,050**	52,917,122	**137,959,543**	138,570,188

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Company Registration No: 201134046D)

C. CONDENSED INTERIM STATEMENTS OF EQUITY

		← Attributable to equity holders of the Company →			
		Share capital	**Capital reserve**	**Accumulated losses**	**Total equity**
Group (Unaudited)	**Notes**	**S$**	**S$**	**S$**	**S$**
2027					
At 30 June 2026		**209,329,342**	**(1,769,096)**	**(154,643,124)**	**52,917,122**
Total comprehensive loss for the period		**-**	**-**	**(5,826,072)**	**(5,826,072)**
At 30 September 2026		**209,329,342**	**(1,769,096)**	**(160,469,196)**	**47,091,050**
2026					
At 30 June 2025		191,464,336	(5,077,737)	(130,746,068)	55,640,531
Total comprehensive loss for the period		-	-	(6,480,537)	(6,480,537)
At 30 September 2025		191,464,336	(5,077,737)	(137,226,605)	49,159,994

		← Attributable to equity holders of the Company →			
		Share capital	**Capital reserve**	**Accumulated losses**	**Total equity**
Company (Unaudited)	**Notes**	**S$**	**S$**	**S$**	**S$**
2027					
At 30 June 2026		**209,329,342**	**(795,077)**	**(69,964,077)**	**138,570,188**
Total comprehensive loss for the period		**-**	**-**	**(610,645)**	**(610,645)**
At 30 September 2026		**209,329,342**	**(795,077)**	**(70,574,722)**	**137,959,543**
2026					
At 30 June 2025		191,464,336	(4,103,718)	(55,679,741)	131,680,877
Total comprehensive loss for the period		-	-	(748,877)	(748,877)
At 30 September 2025		191,464,336	(4,103,718)	(56,428,618)	130,932,000

SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD.
(Company Registration No: 201134046D)

D. CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS

		Group	
		Three months ended	
		30 September 2026 (Unaudited)	30 September 2025 (Unaudited)
	Note	S$	S$
Cash flows from operating activities			
Loss after tax		**(5,826,072)**	(6,480,537)
Adjustments for:			
Depreciation for property, plant and equipment	10	**2,621,861**	2,885,006
Amortisation of intangible assets		**1,145**	2,285
Gain on lease modification		**-**	(28,983)
Income from sublease		**(93,590)**	(78,749)
Interest income		**(5,467)**	-
Interest expenses		**1,033,942**	924,826
Operating cash flow before working capital changes		**(2,268,181)**	(2,776,152)
Changes in working capital:			
Inventories		**(23,902)**	(12,111)
Trade and other receivables		**(492,225)**	(145,796)
Other assets		**(48,304)**	(156,489)
Trade and other payables		**(2,096,349)**	2,625,735
Net cash used in operating activities		**(4,928,961)**	(464,813)
Cash flows from investing activities			
Purchases of property, plant and equipment		**(152,041)**	(129,395)
Sublease income received		**93,547**	71,078
Net cash used in investing activities		**(58,494)**	(58,317)

D. CONDENSED INTERIM CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

	Note	Group Three months ended 30 September 2026 (Unaudited) S$	 30 September 2025 (Unaudited) S$
Cash flows from financing activities			
Changes in restricted cash		**-**	(230,000)
Proceeds from loans from shareholders		**-**	3,000,000
Principal repayment of loans from shareholders		**(1,345,293)**	(87,438)
Principal repayment of bank borrowings		**(474,528)**	(593,998)
Principal payment of lease liabilities		**(793,240)**	(689,225)
Interest paid on bank borrowings		**(19,892)**	(44,003)
Interest paid on lease liabilities		**(320,952)**	(316,547)
Net cash (used in)/generated from financing activities		**(2,953,905)**	1,038,789
Net (decrease)/increase in cash and cash equivalents		**(7,941,360)**	515,659
Cash and cash equivalents at beginning of financial period		**14,192,276**	2,078,309
Cash and cash equivalents at end of financial period [(a)]		**6,250,916**	2,593,968

Note:

(a) For the purposes of the cash flow statement, cash and cash equivalents exclude restricted cash balances. These restricted amounts are included in the total cash and bank balances presented on the balance sheet, and hence the figures may not be directly comparable.

E. NOTES TO THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

1. Corporate information

The Company is incorporated and domiciled in Singapore. The address of its registered office and principal place of business is located at 1 Biopolis Drive #02-01 Amnios Singapore 138622. The Company's registration number is 201134046D. The Company is listed on the Catalist of the Singapore Exchange Securities Trading Limited ("**SGX-ST**").

The principal activity of the Company is that of an investment holding company.

The principal activities of the Group are:

(a) to carry on the business of clinic and other general medical services;
(b) sale of pharmaceuticals, surgical and consumables;
(c) to carry on the business of oncology, clinic and other general medical services; and
(d) to carry on the business of manufacture of medical research and clinic diagnostic instruments and supplies.

2. Basis of preparation

The condensed interim consolidated financial statements for the three months ended 30 September 2026 have been prepared in accordance with SFRS(I) 1-34 *Interim Financial Reporting* issued by the Accounting Standards Council Singapore.

The condensed interim consolidated financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group's financial position and performance of the Group since the last annual financial statements for the financial year ended 30 June 2026.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The condensed interim consolidated financial statements are presented in Singapore dollar which is the Company's functional currency.

2.1 New or amended Standards adopted by the Group

The Group has adopted the new or amended SFRS(I) and Interpretations of SFRS(I) ("INT SFRS(I)") that are mandatory for application for the current reporting period. Changes to the Group's accounting policies have been made as required, in accordance with the transitional provisions in the respective SFRS(I) and INT SFRS(I).

The adoption of these new or amended SFRS(I) and INT SFRS(I) did not result in substantial changes to the Group' accounting policies and had no material effect on the amounts reported for the current or prior interim periods.

2. Basis of preparation (Continued)

2.2 Going concern

For the three months financial period ended 30 September 2026, the Group reported a loss after tax of S$5,826,072 from continuing operations. As at 30 September 2026, the Group's current liabilities exceeded its current assets by S$28,419,102.

Nevertheless, the accompanying financial statements have been prepared on a going concern basis as a result of the key assumptions that have been made which are dependent on the outcome of certain future events as follows:-

(a) the Group has obtained consent from a subsidiary of the controlling shareholder for the extension of the tenures of the loans with aggregate principal amounts of up to S$22 million until 31 December 2027, please refer to the Company's announcement dated 7 November 2026 for more details;

(b) the Group will be able to obtain further financial support from a subsidiary of the controlling shareholder and a director of the Company for collectively up to S$2 million; and

(c) management has evaluated its forecasted cash flows over the next twelve months from the end of the financial period ended 30 September 2026 (including the above inflow of sources of funds) and other information highlighted in Section F Note 7 of this announcement, and is of the view that the Group is able to meet its obligations as and when they fall due.

If the above-mentioned support comes through and if the management's expectations of patient and project flows (as described below in Section F: Note 7) materialise, the Board of Directors concurs with the management that the Company has no going concern issues and the Group has sufficient funds to meet its financial obligations as and when they fall due. The Board of Directors also confirms that, to the best of its knowledge, all material disclosures have been provided for trading of the Company's securities in an orderly manner.

3. Use of judgements and estimates

In preparing the condensed interim consolidated financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

The significant judgements made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the consolidated financial statements as at and for the financial year ended 30 June 2026.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future periods affected.

(i) Impairment assessment of the Group's property, plant and equipment

The Group assesses at the end of each financial year whether there are any indicators of impairment for property, plant and equipment.

The Group considers the individual clinics as a separate cash-generating unit ("**CGU**") and has carried out assessments on each of the components' carrying amounts to identify whether there are indicators of impairment. The recoverable amount is determined based on the higher of the CGU's value-in-use and fair value less cost of disposal. External valuation on components with impairment indicators is obtained from an independent professional valuer when the internal assessments indicate impairment indicators.

3. Use of judgements and estimates (Continued)

(ii) Estimation of the recoverable value of the Company's investment in subsidiaries

The Group assesses at the end of each financial year whether there are any indicators of impairment for the recoverable value of the Company's investment in subsidiaries.

An estimate of the recoverable value of the Company's investment in subsidiaries is made when there is indication that impairment exists. The recoverable amount is determined based on the market approach after considering control and marketability adjustments. The recoverable value of the Company's investments in subsidiaries represents management's best estimate as at the end of the reporting period.

(iii) Impairment of the Company's other receivables from subsidiaries

The Group assesses at the end of each financial year whether there are any indicators of impairment for the Company's other receivables from subsidiaries.

For other receivables from subsidiaries, the Group and Company applies either a 12-month expected credit loss or lifetime credit loss, depending on whether there has been a significant increase in credit risk since initial recognition. If a significant increase in credit risk of a receivable has occurred since initial recognition, impairment is measured based on lifetime expected credit losses.

These financial assets are assessed as credit-impaired when one or more events that have a detrimental impact on the estimated future cash flows of that financial asset have occurred. Evidence that a financial asset is credit-impaired includes observable data about events, including but not limited to significant financial difficulty of the counterparties or a breach of contract, such as a default or past due event.

4. Seasonal operations

The Group's businesses are not affected significantly by seasonal or cyclical factors during the financial period.

5. Segment and revenue information

Business segments

The Group has the following strategic business units.

(a) Medical Diagnostics and Treatments, through subsidiaries which cover the sub-segments below:
- Cancer-related diagnostics and theranostics treatments;
- General diagnostics and health screening; and
- Aesthetic services

(b) Radiation Therapy and Medical Oncology Services, through a subsidiary which covers the sub-segments below:
- Proton beam therapy;
- Photon radiation therapy; and
- Medical oncology

(c) Investment holding

	Medical diagnostics and treatments	Radiation therapy and medical oncology services	**Total for continuing operations**	Investment holding - discontinued operations	**Total for continuing and discontinued operations**
	S$	S$	S$	S$	S$
For three months ended 30 September 2026					
Segment revenue					
Clinical and medical services fees	**3,214,057**	**1,296,856**	**4,510,913**	**-**	**4,510,913**
Income from services to third parties	**3,000**	**-**	**3,000**	**-**	**3,000**
Total revenue	**3,217,057**	**1,296,856**	**4,513,913**	**-**	**4,513,913**
Reconciliations:					
LBITDA	**(59,343)**	**(2,157,194)**	**(2,216,537)**	**-**	**(2,216,537)**
Interest income	**-**	**5,469**	**5,469**	**-**	**5,469**
Depreciation of property, plant and equipment	**(455,034)**	**(2,166,827)**	**(2,621,861)**	**-**	**(2,621,861)**
Amortisation of intangible assets	**-**	**(1,145)**	**(1,145)**	**-**	**(1,145)**
Interest expenses	**(86,069)**	**(905,929)**	**(991,998)**	**-**	**(991,998)**
Loss before tax	**(600,446)**	**(5,225,626)**	**(5,826,072)**	**-**	**(5,826,072)**
Segment assets	**9,144,362**	**113,114,198**	**122,258,560**	**-**	**122,258,560**
- Addition to property, plant and equipment	**10,274**	**141,767**	**152,041**	**-**	**152,041**
Segment liabilities	**10,927,118**	**64,240,392**	**75,167,510**	**-**	**75,167,510**

5. Segment and revenue information (Continued)

	Medical diagnostics and treatments	Radiation therapy and medical oncology services	**Total for continuing operations**	Investment holding - discontinued operations	**Total for continuing and discontinued operations**
	S$	S$	S$	S$	S$
For three months ended 30 September 2025					
Segment revenue					
Clinical and medical services fees	2,881,854	687,008	3,568,862	-	3,568,862
Income from services to third parties	553,000	-	553,000	-	553,000
Total revenue	3,434,854	687,008	4,121,862	-	4,121,862
Reconciliations:					
EBITDA/(LBITDA)	351,022	(3,029,540)	(2,678,518)	(2,021)	(2,680,539)
Interest income	-	5,362	5,362	-	5,362
Depreciation of property, plant and equipment	(720,796)	(2,164,210)	(2,885,006)	-	(2,885,006)
Amortisation of intangible assets	-	(2,286)	(2,286)	-	(2,286)
Interest expenses	(68,329)	(849,739)	(918,068)	-	(918,068)
Loss before tax	(438,103)	(6,040,413)	(6,478,516)	(2,021)	(6,480,537)
Segment assets	11,102,144	116,587,961	127,690,105	22,487	127,712,592
- Addition to property, plant and equipment	4,672,121	73,548	4,745,669	-	4,745,669
Segment liabilities	12,802,889	65,745,862	78,548,751	3,847	78,552,598

6. Financial assets and financial liabilities

Set out below is an overview of the financial assets and financial liabilities of the Group as at 30 September 2026 and 30 June 2026:

	30 September 2026	30 June 2026
	S$	**S$**
Group		
Financial assets, at amortised cost	**13,980,195**	21,362,376
Financial liabilities, at amortised cost	**69,146,488**	73,353,083
Company		
Financial assets, at amortised cost	**5,972,311**	17,631,917
Financial liabilities, at amortised cost	**28,841,178**	32,243,210

7. Related party transactions

In addition to the information disclosed elsewhere in the financial statements, the following transactions took place between the Group and related parties at terms agreed between the parties:

Transactions with related parties

	Group	
	For three months ended	
	30 September 2026	30 September 2025
	S$	S$
Medical consultancy fees paid to related parties*	**391,838**	256,705
Purchase of consumable from a related party	**9,999**	-
Referral of patients by related parties	**30,035**	14,973
Drawdown of loans from shareholders	**-**	3,000,000
Repayment of shareholders' loan	**1,345,293**	87,438
Interest expense on loans from shareholders	**456,413**	354,152
Sublease income from a related party*	**93,590**	78,749

* Related parties refer to companies which are controlled by the directors of the Company and its subsidiaries. Related parties also include key management personnel having authority and responsibility for planning, directing and controlling the activities of the entity, directly or indirectly, including any director (whether executive or otherwise) of that entity.

8. Income tax expense

The Income tax expense is recognised based on management's estimate of the weighted average effective annual income tax rate expected for the three months financial period. The estimated average annual tax rate used for both three months ended 30 September 2026 and 30 September 2025 is 0%.

Deferred tax assets are not recognised in the financial statements as it is uncertain there will be sufficient future taxable profits that will allow the deferred tax assets to be recovered.

9. Net asset value

	Group		Company	
	30 September 2026	**30 June 2026**	**30 September 2026**	**30 June 2026**
Net asset value attributable to owners of the Company (S$)	**47,091,050**	52,917,122	**137,959,543**	138,570,188
Number of ordinary shares in issue (excluding treasury shares)	**1,724,092,498**	1,724,092,498	**1,724,092,498**	1,724,092,498
Net asset value per ordinary share (cents per share)	**2.73**	3.07	**8.00**	8.04

10. Property, plant and equipment

Additions

As at 30 September 2026, the Group acquired property, plant and equipment of S$152,041 (as at 30 September 2025: S$157,535).

Addition of ROU assets as at 30 September 2026 was S$ Nil (as at 30 September 2025: S$4,588,134).

Depreciation

During the financial period ended 30 September 2026, the Group's depreciation charge for property, plant and equipment amounted to S$2,621,861 (financial period ended 30 September 2025: S$2,885,006).

Disposal

During the financial period ended 30 September 2026, the Group disposed of property, plant and equipment with carrying amount of S$ Nil (financial period ended 30 September 2025: S$16,326).

11. Share capital

	Group and Company	
	30 September 2026	30 June 2026
Issued share capital	**S$**	**S$**
Beginning of financial period	**209,329,342**	191,464,336
Issuance of shares	**-**	17,865,006
End of financial period	**209,329,342**	209,329,342
No. of ordinary shares		
Beginning of financial period	**1,724,092,498**	1,062,020,642
Issuance of shares	**-**	662,071,856
End of financial period	**1,724,092,498**	1,724,092,498

11. Share capital (Continued)

The Company's share capital consists of ordinary shares of no-par value.

All ordinary shareholders are entitled to receive dividends as and when declared by the Company. All ordinary shares carry one vote per share.

12. Borrowings

Amount repayable in one year or less, or on demand

As at 30 September 2026		As at 30 June 2026	
Secured	**Unsecured ***	**Secured**	**Unsecured ***
S$935,319	**S$23,956,773**	S$1,409,847	S$17,435,811

Amount repayable after one year

As at 30 September 2026		As at 30 June 2026	
Secured	**Unsecured ***	**Secured**	**Unsecured ***
-	**S$3,463,627**	-	S$10,873,469

* Unsecured borrowings include loans from shareholders.

Details of any collateral

Bank borrowings amounting to S$935,319 as at 30 September 2026 (30 June 2026: S$1,409,847) are secured by:

30 September 2026 and 30 June 2026

i. fixed and floating charge over all present and future assets of the Company, Advanced Medicine Oncology Centre and Proton Therapy Pte. Ltd., including the Proton System;
ii. assignment of all rights, interests and benefits under certain contracts; and
iii. corporate guarantee from the subsidiaries.

13. Loans from shareholders

In July 2026, the Group entered into two supplemental agreements with a shareholder to grant the extension of two existing loans for an additional one year from their respective maturity dates, unless varied by mutual agreement between the Company and the shareholder. The extended maturity dates for the loans are 31 December 2027 and 4 September 2027, respectively. The extension will be granted under the same terms and conditions stipulated in the original agreements.

In September 2026, the Group entered into an interest-bearing loan agreement of $3,000,000 with a substantial shareholder. The loan is expected to be disbursed no later than 31 December 2026 and will be repayable 12 months from the date of disbursement.

14. Subsequent events

There are no other known subsequent events which have led to adjustments to this set of interim financial statements.

F. OTHER INFORMATION REQUIRED BY CATALIST RULES APPENDIX 7C

1(d)(ii) Details of any changes in the company's share capital arising from rights issue, bonus issue, subdivision, consolidation share buy-backs, exercise of share options or warrants, conversion of other issues of equity securities, issue of shares for cash or as consideration for acquisition or for any other purpose since the end of the previous period reported on. State the number of shares that may be issued on conversion of all the outstanding convertibles, if any, against the total number of issued shares excluding treasury shares and subsidiary holdings of the issuer, as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year. State also the number of shares held as treasury shares and the number of subsidiary holdings, if any, and the percentage of the aggregate number of treasury shares and subsidiary holdings held against the total number of shares outstanding in a class that is listed as at the end of the current financial period reported on and as at the end of the corresponding period of the immediately preceding financial year.

Please refer to "*E. Notes to the Condensed Interim Consolidated Financial Statements: 11. Share capital*" above for the detailed movement for changes in the Company's share capital.

Treasury Shares
There were no treasury shares as at 30 September 2026 and 2025.

Subsidiary Holdings
There were no subsidiary holdings as at 30 September 2026 and 2025.

1(d)(iii) To show the total number of issued shares excluding treasury shares as at the end of the current financial period and as at the end of the immediately preceding year.

Please refer to *"E. Notes to the Condensed Interim Consolidated Financial Statements: 11. Share capital"* above.

1(d)(iv) A statement showing all sales, transfers, cancellation and/or use of treasury shares as at the end of the current financial period reported on.

Not applicable. There were no sales, transfers, cancellation and/or use of treasury shares during and as at the end of the current financial period reported on.

1(d)(v) A statement showing all sales, transfers, cancellation and/or use of subsidiary holdings as at the end of the current financial period reported on.

Not applicable. There were no subsidiary holdings during and as at the end of the current financial period reported on.

2. Whether the figures have been audited or reviewed, and in accordance with which auditing standard or practice.

The financial statements presented have not been audited or reviewed by the Company's independent auditors.

3. Where the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion (this is not required for any audit issue that is a material uncertainty relating to going concern): -

a. Updates on the efforts taken to resolve each outstanding issue.

In the Group's latest audited financial statements for the financial year ended 30 June 2026 ("FY2026"), Foo Kon Tan LLP, the Group's auditor, has issued a disclaimer opinion in respect of:

(i) Opening balances and comparative information and the financial effect on the current year's figures
(ii) Going concern
(iii) Impairment of property, plant and equipment ("PPE")
(iv) Impairment of the Company's investment in a subsidiary

The management is in the midst of resolving the audit issues raised by the auditor as stated above. Some of the measures are taken or to be taken by the management as below:

1. In end-October the Ministry of Health invited written representations from the Group by 9 November 2026 on proposed modifications to the list of indications for proton beam therapy. If implemented, the revised list would expressly include specified breast and chest wall cancers and defined categories of lung cancer, broadening eligibility beyond the existing indications. A particularly significant expansion would be the inclusion of all cancers being treated with curative intent in patients younger than 25 years, subject to applicable clinical assessment. This is expected to increase the local and foreign patients treated.

2. Under the Service Level Agreement ("SLA") with a Leading Public Hospital and Cancer Group, patients from this hospital and cancer group have commenced proton therapy treatment at the Group's centre since December 2025. The Group is still accrediting radiation oncologists from this Leading Public Hospital and Cancer Group to treat their patients at the Group's centre.

3. In end-January 2026, the Group has also varied the SLA with the Leading Public Group Hospital and Cancer Group to include photon therapy for the patients in addition to proton therapy, and the Group have seen a significant increase in photon therapy patients since March 2026.

4. From the collaboration discussion with a leading private oncology group, the Group has accredited a senior radiation oncologist.

5. The Group has made progress in engaging corporate clients for health screening services. Furthermore, active discussions are underway with local and international medical oncology groups and medical concierge companies to secure foreign patient referrals, with a primary focus on Malaysia, Vietnam and Indonesia.

6. The Group has launched new health access plans to individuals and corporate clients to increase business activities across the Group's entities.

7. Under the Group's first service agreement entered into in July 2025 with one of the world's largest pharmaceutical companies for a clinical research trial, the relevant trial protocols received approval from the US FDA, and began in February 2026 through November 2026. The Group continues to explore further areas of collaboration with the pharmaceutical company, including potential opportunities in nuclear medicine and neurodegenerative disease trials.

The initiatives outlined above are expected to strengthen the Group's financial position and mitigate the going concern uncertainties raised by the Company's auditor. These initiatives are aimed at driving revenue growth and improving cash flow through increased patient intake, mitigating the risk of impairment of PPE as raised in issue (iii) through optimised machinery utilisation, and enhancing the underlying performance of the subsidiary to address the investment impairment risks as raised in issue (iv). For issue (i) above, the Company will continue to implement these initiatives to address and strengthen the Group's financial performance and position.

b. Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.

The Board confirms that the impact of all outstanding audit issues on the financial statements has been adequately disclosed.

Please refer to "*E. Notes to the Condensed Interim Consolidated Financial Statements: 3. Use of judgements and estimates*" above.

4. Earnings per ordinary share of the group for the current period reported on and the corresponding period of the immediately preceding financial year, after deducting any provision for preference dividends.

	Group	
	Three months ended	
Continuing operations	**30 September 2026**	30 September 2025
Net loss from continuing operations attributable to equity holders of the Company (S$)	**(5,826,072)**	(6,478,516)
Weighted average number of ordinary shares	**1,724,092,498**	1,062,020,642
Basic and diluted loss per share (cents per share)	**(0.34)**	(0.61)
Discontinuing operations		
Net loss from discontinuing operations attributable to equity holders of the Company (S$)	**-**	(2,021)
Weighted average number of ordinary shares	**1,724,092,498**	1,062,020,642
Basic and diluted loss per share (cents per share)	**-**	**

** Amount less than 0.001

5. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. The review must discuss: -

a. any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and

b. any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.

Review for the performance of the Group for 3 months ended 30 September 2026 ("Q1 FY27") and 30 September 2025 ("Q1 FY26") respectively.

Consolidated Statement of Comprehensive Income

Q1 FY26 vs Q1 FY27

(a) Revenue

The Group's revenue for Q1 FY27 increased by S$0.39 million from S$4.12 million in Q1 FY26 to S$4.51 million in Q1 FY27. Revenue from the Medical Diagnostics and Treatments segment decreased by S$0.22 million to S$3.21 million in Q1 FY27. This was mainly attributable to a decrease in income from clinical research services rendered to third parties, which was partially offset by an increase in revenue contribution from the clinical and medical services segment. Revenue from the Radiation Therapy and Medical Oncology segment increased significantly from S$0.68 million in Q1 FY26 to S$1.30 million in Q1 FY27, which was mainly driven by a higher number of patients, notwithstanding a shift in patient profile mix, with a higher proportion of lower-priced treatments resulting in lower average revenue per case.

(b) Other gains/(losses)

The Group recorded other gains of S$0.03 million in Q1 FY27, compared to losses of S$0.01 million in Q1 FY26 mainly due to foreign exchange gains in Q1 FY27 compared to foreign exchange losses in Q1 FY26, both arising from payment to a supplier.

(c) Medical consultancy fees

The Group recorded medical consultancy fees of S$0.46million in Q1 FY27, an increase of 42% compared to S$0.33 million in Q1 FY26, mainly due to an increase in the doctors' earnings for the aesthetics department under Medical Diagnostics and Treatments segment as a result of the increase of revenue recorded under aesthetics department from the Medical Diagnostics and Treatments segment in Q1 FY27.

(d) Purchase of inventories

The Group's purchase of inventories increased by S$0.06 million from S$0.27 million in Q1 FY26 to S$0.33 million in Q1 FY27. The increase was mainly attributable to the higher revenue contribution from the clinical and medical services segment, resulting in higher inventory requirements to support its business activities.

(e) Depreciation of property, plant and equipment

The Group recorded depreciation expenses of S$2.62 million in Q1 FY27, compared to S$2.89 million in Q1 FY26, representing a decrease of approximately S$0.27 million. The decrease was mainly attributable to certain property, plant and equipment having been fully depreciated or having lower depreciable values during Q1 FY27.

(f) Amortisation of intangible assets

The decrease in amortisation of intangible assets during the current financial period was mainly attributable to certain intangibles having been fully amortised or having lower amortisable values during Q1 FY27.

(g) Short-term rental of premises

Short-term rental of premises decreased by 13% from Q1 FY26 to Q1 FY27 due to termination of a medical equipment.

(h) Loss after tax

The loss after tax decreased by 10% from S$6.48 million in Q1 FY26 to S$5.83 million in Q1 FY27 mainly due to the factors mentioned above.

Consolidated Statement of Financial Position

(a) Non-current assets

The Group recorded non-current assets of S$111.51 million as at 30 September 2026, compared to S$113.93 million as at 30 June 2026, a decrease of S$2.42 million mainly due to the depreciation of PPE and amortisation of intangible assets during the period, partially offset by the purchase of PPE of S$0.15 million (refer to Section E: Note 10).

(b) Current assets

The Group recorded current assets of S$10.75 million as at 30 September 2026, compared to S$18.17 million as at 30 June 2026, net decrease of S$7.43 million is mainly due to a decrease in cash and bank balances of S$7.94 million, and partially offset by the increase in trade and other receivables due to slower collection from customers. Further details of the Group's cash flows are set out in section "Consolidated Statement of Cash Flows" below.

(c) Non-current liabilities

Non-current liabilities decreased by S$8.46 million to S$36.00 million as at 30 September 2026. The decrease was mainly due to the reclassification of the following from non-current liabilities to current liabilities (i) loans from shareholders of S$7.41 million due to contractual repayment falling within the next 12 months; and (ii) reclassification of lease liabilities of S$0.82 million.

(d) Current liabilities

The Group's current liabilities increased from S$34.73 million as at 30 June 2026 to S$39.17 million as at 30 September 2026, representing a net increase of S$4.44 million. The increase was mainly attributable to the reclassification of loans from shareholders as set out above as well as the accompanying interest charged on the shareholders loans during the period, which was partially offset by the decrease in trade and other payables of S$1.91 million and the repayment of bank borrowings of S$0.47 million during Q1 FY27.

The Group is in a net current liability position of S$28.42 million as at 30 September 2026. Based on the factors as elaborated further in section 2.2 of Note E explaining the Group's going concern assessment, and the Board is of the view that the Group will have sufficient funds to meet its financial obligations as and when they fall due.

Consolidated Statement of Cash Flows

Q1 FY26 vs Q1 FY27

(a) Cash flows from operating activities

Net cash used in operating activities was recorded at S$4.93 million. This was derived from operating cash flows before working capital changes of S$2.27 million, mainly due to the Group recording a loss after tax of S$5.83 million for Q1 FY27, mainly adjusted for interest expenses of S$1.03 million and depreciation for property, plant and equipment of S$2.62 million. The decrease in working capital is mainly due to the increase in trade and other receivables of S$0.49 million due to slower collection from customers, partially offset by higher settlement of trade and other payables by S$2.10 million in Q1 FY27.

(b) Cash flows from investing activities

The Group's net cash generated from investing activities in Q1 FY27 primarily relates to purchase of PPE of S$0.15 million and partially offset by sublease income received of S$0.09 million.

(c) Cash flows from financing activities

Net cash used in financing activities in Q1 FY27 amounted to S$2.95 million mainly due to:

i) Repayment of shareholders loan of S$1.35 million;
ii) Repayment of lease liabilities and its corresponding finance costs of S$1.11 million; and
iii) Repayment of bank loan and its corresponding interest expense of S$0.49 million.

6. Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.

Not applicable.

7. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Singapore continues to maintain its position as a regional hub for highly specialised healthcare, including oncology. While foreign patient volumes remain below pre-pandemic levels, demand for complex and high-value treatments continues to support the segment[1]. In oncology, Singapore is one of the few countries in Southeast Asia offering proton beam therapy ("PBT"), providing an opportunity to serve both local and regional patients requiring specialised radiation treatment[2].

The operating environment for specialised oncology services remains dependent on factors including the pace of patient referrals and conversion, patient eligibility and accessibility, insurance coverage, and competition from alternative treatment modalities and regional healthcare providers. Singapore's established healthcare infrastructure, clinical expertise and reputation for quality of care continue to support its position as a destination for complex medical treatment[3].

Against this backdrop, the Group continues to strengthen its referral channels and clinical collaborations. Key developments which may affect the Group over the next 12 months include:

- **Leading Public Hospital and Cancer Group:** In January 2026, the two-year Service Level Agreement was varied to include the provision of photon therapy treatment for patients, in addition to proton therapy. The expanded scope provides an additional referral channel for the Group's radiotherapy services.

- **Private Oncology Group Collaboration:** From the collaboration discussion with a leading private oncology group, the Group has accredited a senior radiation oncologist.

- **Centre for Clinical Pharmacology**: Under the first service agreement entered into in July 2025 with one of the largest global pharmaceutical companies for a clinical research trial, the relevant trial protocols received approval from the US FDA in February 2026. The Group continues to explore further areas of collaboration with the pharmaceutical company, including potential opportunities in nuclear medicine and neurodegenerative disease trials.

- The Group is exploring the use of proton beams in proton-boron fusion therapy, which may contribute to improved proton beam machine utilisation in the future.

- **Corporate Exercise:** The Company expects to undertake appropriate corporate exercises to support the Group's working capital requirements and ongoing operations.

Taken together, these developments are expected to broaden the Group's referral channels and clinical collaborations over the next 12 months. However, the timing and extent of any resulting increase in patient volumes and revenue will depend on, among other factors, the conversion of referral pipelines, patient eligibility and demand, the implementation and development of clinical collaborations, and prevailing competitive and market conditions.

In assessing the Group's ability to continue as a going concern, the Board has considered the Group's current financial position and management's assessment of projected cash flows, expected patient volumes and operational requirements as well as bases illustrated in the above section 2.2 of Note E. Based on this assessment, the Board is satisfied that the Group has adequate resources to meet its obligations and continue as a going concern for at least the next twelve months.

[1] https://www.aseanbriefing.com/news/singapores-medical-tourism-industry-growth-opportunities-and-future-trends/
[2] https://www.nccs.com.sg/news/patient-care/more-than-300-in-singapore-have-received-proton-beam-therapy-for-cancer
[3] https://www.nccs.com.sg/news/others/fewer-foreign-patients-in-singapore-but-more-coming-for-critical-and-complex-care

8. Dividend

a. Current Financial Period Reported On: Any dividend declared for the current financial period reported on?

No dividends have been declared or recommended for the current reporting financial period.

b. Corresponding Period of the Immediately Preceding Financial Year: Any dividend declared for the corresponding period of the immediately preceding financial year?

Not applicable.

c. Date payable:

Not applicable.

d. Books closure date:

Not applicable.

e. The date on which Registrable Transfers received by the company (up to 5.00pm) will be registered before entitlements to the dividend are determined:

Not applicable.

9. If no dividend has been declared/recommended, a statement to that effect and the reason(s) for the decision.

No dividends have been declared or recommended for the reported financial period as the Company recorded a loss for the financial period.

10. If the group has obtained a general mandate from shareholders for interested person transactions ("IPT"), the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Company did not obtain a general mandate from its shareholders for IPTs. Save for the below, there were no other IPTs amounting to S$100,000 and above since 30 June 2026:

Name of interested person	Nature of relationship	Aggregate value of all interested person transactions during the financial year under review (excluding transactions less than S$100,000 and transactions conducted under shareholders' mandate pursuant to Rule 920)	Aggregate value of all interested person transactions conducted under shareholders' mandate pursuant to Rule 920 (excluding transactions less than S$100,000)
Dr Djeng Shih Kien ("Dr Djeng")	The Chief Executive Officer and Executive Director of the Company, and a shareholder holding approximately 8.19% shareholding interest in the Company as at the date of this announcement.	S$96,000 (1)	Not applicable
Espeetex Sdn. Bhd. (the "Espeetex")	One controlling shareholder of the Company, holding approximately 20.33% shareholding interest in the Company as at the date of this announcement.	S$1,199,191 (2)(3)(4)	Not applicable

(1) The Company had entered into a loan agreement dated 8 November 2026 between the Company and Dr Djeng in relation to the loan of aggregate principal amount of up to S$1,200,000.

(2) The Company had entered into two supplemental agreements dated 24 July 2026 and seven supplemental agreements dated 7 November 2026 with Espeetex, respectively, to vary the terms of the respective intercompany loan agreements between the Company and Espeetex in relation to loans of aggregate principal amounts of up to S$2,000,000, S$4,000,000, S$800,000, S$5,000,000, S$1,200,000, S$6,000,000, S$1,500,000 and S$1,500,000 respectively, by extending the respective loan tenures until 31 December 2027.

(3) The Company had entered into a loan agreement dated 7 November 2026 between the Company and Espeetex in relation to the loan of aggregate principal amount of up to S$800,000.

(4) From 30 June 2026 to the date of this announcement, the total value of all interested person transactions (excluding transactions less than S$100,000) with Espeetex, Berjaya Corporation Berhad and its associates is approximately S$1,199,191, being 2.27% of the Group's latest audited net tangible assets in respect of FY2026. Save as disclosed herein, there were no other interested person transactions (including transactions less than S$100,000) with Espeetex, Berjaya Corporation Berhad and its associates during the three months ended 30 September 2026.

11. Use of Net Proceeds from the Rights cum Warrants Issue

The Company refers to the net proceeds amounting to S$14.94 million (excluding deducting estimated costs and expenses of S$0.33 million) (the "**Rights Net Proceeds**") raised from the Rights cum Warrants Issue on 23 June 2026.

As at date of this announcement, the status on the utilisation of the Rights Net Proceeds is as follows:

	Amount allocated as disclosed in the OIS S$'000	Amount utilised as at the date of this announcement S$'000	Balance as at 8 November 2026 S$'000
General working capital [(1)]	9,441	7,934 [(2)]	1,507
Repayment of loan from a Shareholder [(3)]	1,200	1,200	-
System maintenance and software upgrades	3,800	2,035	1,765
System revamp and CAPEX	500	185	315
Total	14,941	11,353	3,587

Note:

(1) As set out in the Offer Information Statement ("**OIS**") dated 2 June 2026, the Company had received Prepayments from certain Undertaking Shareholders amounting to an aggregate of S$3.90 million, which had been fully applied towards the Company's working capital requirements, comprising mainly payroll expenses and maintenance fees for medical equipment, of which the breakdown of its utilisation is set out in the Company's announcement dated 16 July 2026. Please refer to the OIS and the Company's announcements dated 13 February 2026 and 22 April 2026 for further information in relation to the Prepayments.

(2) Amount utilised for general working capital of S$8.13 million mainly due to the payment for payroll expenses of the Group's employees and Directors' fees of approximately S$3.49 million, rental fees and other related expenses of the Group of approximately S$1.81 million, utilities charges and professional fees of the Group amounting to approximately S$1.26 million and S$0.34 million.

(3) The loan was granted by one of the Company's Shareholders to the Company to fund its working capital. Please refer to the OIS for further details in relation to the Shareholder's loan. The loan was utilised for i) system maintenance of approximately S$0.80 million, ii) payroll expenses of approximately S$0.33 million, and iii) rental and other related expenses of the Group amounting to approximately S$0.07 million.

The above utilisation is in accordance with the intended use of Rights Net Proceeds as set out in the OIS.

The Company will continue to make periodic announcements via SGXNet on the utilisation of the Rights Net Proceeds as and when such proceeds are materially disbursed.

12. Confirmation that the issue has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Listing Manual.

The Company confirms that it has procured undertakings from all its directors and executive officers (in the format set out in Appendix 7H) under Rule 720(1) of the Catalist Listing Manual.

13. Negative confirmation pursuant to Rule 705(5) of the Catalist Rules

The Board of Directors of the Company confirms that to the best of its knowledge, nothing has come to its attention which may render the financial results for the nine months ended 30 September 2026 to be false or misleading in any material aspect.

14. Disclosures required pursuant to Rule 706A of the Catalist Rules

During Q1 FY27, the Company did not acquire any shares resulting in any company becoming a subsidiary or associated company or increasing its shareholding percentage in any subsidiary. Additionally, the Company did not dispose of any shares resulting in a company ceasing to be a subsidiary corporation or associated company or decreasing its shareholding percentage in any subsidiary corporation.

BY ORDER OF THE BOARD

Dr Djeng Shih Kien
Executive Director and Chief Executive Officer
8 November 2026

Yeo Seng Lye Paul
Executive Director and Chief Operating Officer

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the **Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms. Ng Shi Qing, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.